Program

Program

Note: Timings below are listed in Australian Eastern Daylight Time (AEDT). To check your time zone please click here.

MONDAY 22 MARCH 2021

RANZCR Radiation Oncology Trainee SMART Workshop

 

1030 – 1050 Welcome and Introduction
Dr Giuseppe Sasso, President of TROG Cancer Research

Introduction of SMART Facilitators and Biostatisticians

1050 – 1105 Introduction to Critical Appraisal – “Do we really need it? Aren’t papers already peer reviewed?”
Dr Kristy Robledo, Prof Val Gebski, Mr Chris Brown & Dr Trang Pham
1105 – 1120 Issues with Randomised Controlled Trials: Key Concepts and Question Time
Dr Kristy Robledo, Prof Val Gebski & Mr Chris Brown

  • Randomisation
  • Strata
  • Allocation concealment
1120 – 1200 Small Group Session 1
Dr Kristy Robledo, Prof Val Gebski, Mr Chris Brown, A/Prof Sandra Turner, Dr Keen Hun Tai, A/Prof Shankar Siva, Dr Rahul Mukherjee, A/Prof David Pryor, Dr Eric Hau, Dr Jane Ludbrook, A/Prof Gerry Hanna & A/Prof Puma Sundaresan
1200 – 1245 LUNCH BREAK
Meeting Hub | Meet with Delegates in the Meeting Hub
1245 – 1300 Time to Event Concepts: Key Concepts and Question Time
Dr Kristy Robledo, Prof Val Gebski & Mr Chris Brown

  • Censored Observations
  • Survival Curves
  • Estimates from These Curves and Comparisons
  • Follow-Up Issues
  • Comparison
  • Quantifying Risk
1300 – 1350 Small Group Session 2
Dr Kristy Robledo, Prof Val Gebski, Mr Chris Brown, A/Prof Sandra Turner, Dr Keen Hun Tai, A/Prof Shankar Siva, Dr Rahul Mukherjee, A/Prof David Pryor, Dr Eric Hau, Dr Jane Ludbrook, A/Prof Gerry Hanna & A/Prof Puma Sundaresan
1350 – 1405 Local Guest Speaker
Prof Michael Barton OAM
Radiation Oncologist, University of New South Wales
1405 – 1420 Local Guest Speaker
A/Prof. Shankar Siva
Radiation Oncologist, Peter MacCallum Cancer Centre
1420 – 1430 Guest Speaker Question Time
1430 – 1445 AFTERNOON BREAK
Meeting Hub | Meet with Delegates in the Meeting Hub
1445 – 1500 Interpretation of Clinical Trial Results: Key Concepts and Question Time
Dr Kristy Robledo, Prof Val Gebski & Mr Chris Brown

  • Intention to Treat / per Protocol
  • Multiple Outcomes
  • Tweaking Study Designs
  • Subgroups Analyses
  • Interim Analyses
1500 – 1550 Small Group Session 3
Dr Kristy Robledo, Prof Val Gebski, Mr Chris Brown, A/Prof Sandra Turner, Dr Keen Hun Tai, A/Prof Shankar Siva, Dr Rahul Mukherjee, A/Prof David Pryor, Dr Eric Hau, Dr Jane Ludbrook, A/Prof Gerry Hanna & A/Prof Puma Sundaresan
1550 – 1630 Open Forum Q&A
Dr Trang Pham, A/Prof Sandra Turner, Dr Keen Hun Tai, A/Prof Shankar Siva, Dr Rahul Mukherjee, A/Prof David Pryor, Dr Eric Hau, Dr Jane Ludbrook, Mr Chris Brown, Dr Kristy Robledo, Prof Val Gebski, A/Prof Gerry Hanna & A/Prof Puma Sundaresan
1630 Wrap Up – Closing
Dr Trang Pham

 

TUESDAY 23 MARCH 2021

0900 – 1030 OPENING PLENARY
0900 – 0905 Acknowledgement of Country
Mr Luther Cora
0905 – 0915 Official Welcome & Housekeeping
Dr Renee Finnigan & Dr John Shakeshaft
0915 – 0945 Update of NRG Activities and Future Directions for Collaborative Research
Prof Sue Yom
0945 – 1015 Recent Developments/Emerging Research in Head & Neck/Lung Cancer
Prof Sue Yom
1015 – 1030 TROG Scientific Committee Update
Prof Trevor Leong
1030 – 1045

MORNING BREAK

Meeting Hub | Meet with Delegates in the Meeting Hub
Exhibition | Browse the Exhibition

1045 – 1215 PLENARY 2: LUNG CANCER RESEARCH PORTFOLIO

BREAKING NEWS: TRIALS WITH NEW RESULTS

Chairs: Dr Fiona Hegi-Johnson & Dr Yu Yang Soon

1045 – 1100 TROG 13.01 / ALTG 13.001 SAFRON II – Stereotactic Ablative Fractionated Radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the Lung: A Randomised Phase II Trial (Cat A | Open)
A/Prof Shankar Siva

PROPOSALS UNDER DEVELOPMENT / TRIALS IN START-UP

Chairs: Dr Jane Ludbrook & Dr Fiona Hegi-Johnson

1100 – 1115 TROG 20.01 CHEST RT – Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer with Thoracic Radiotherapy (Cat A | Start Up)
Dr Eric Hau

OPEN TRIALS WITH CHALLENGES

Chairs: Dr Yu Yang Soon & Dr Jane Ludbrook

1115 – 1125 TROG 17.02 OUTRUN – Randomised Phase II Trial of Osimertinib with or without Stereotactic Radiosurgery for EGFR Mutated NSCLC with Brain Metastases (Cat A | Open)
Dr Fiona Hegi-Johnson & A/Prof Chee Lee

1125 – 1215

 

Horizon Scanning

Chair: Dr Fiona Hegi-Johnson

Dr Jane Ludbrook
Dr Yu Yang Soon
Dr Eric Hau
A/Prof Chee Lee
Prof Shalini Vinod

1215 – 1245

LUNCH BREAK

Meeting Hub | Meet with Delegates in the Meeting Hub
Exhibition | Browse the Exhibition

1245 – 1415 PLENARY 3: HEAD, NECK AND SKIN CANCER RESEARCH PORTFOLIO TECHNICAL RESEARCH WORKSHOP:
TROG RADIATION THERAPY QUALITY ASSURANCE

Chairs: Dr Charles Lin & Dr Lachlan McDowell

1245 – 1250
Introduction and Housekeeping
Dr Charles Lin

Breaking Trials with New Results or Updates

1250 – 1255
TROG 14.03 EORTC 1219 – A Blind Randomized Multicentre Study of Accelerated Fractionated Chemo-Radiotherapy with or without the Hypoxic Cell Radiosensitizer Nimorazole, using a 15-Gene Signature for Hypoxia in the Treatment of Squamous Cell Carcinoma of the Head and Neck
Prof Sandro Porceddu

1255 – 1305
TROG 08.05 WBRT – Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma – A Randomised Phase III Trial
A/Prof Angela Hong

1305 – 1310
TROG 12.01 HPV OROPHARYNX – A Randomised Trial of Weekly Cetuximab and Radiation versus Weekly Cisplatin and Radiation in Good Prognosis Loco Regionally Advanced HPV-Associated Oropharyngeal Squamous Cell Carcinoma

1310 – 1325
Secondary Analyses

RTQA (TROG 12.01)
Prof June Corry

PRO (TROG 12.01)
Dr Lachlan McDowell

SHOUT (TROG 12.01)
Dr Laurelie Wishart

Prognostic Indicators
Dr Sweet Ping Ng

Re-Hum
Dr Charles Lin on behalf of Dr Noel Aherne

Proposals Under Development/Trials in Start Up

1325 – 1330
TROG 19.07 UTILITY Unilateral Treatment in all Well-Lateralized Tonsillar Primary Tumours
Dr Lachlan McDowell

1330 – 1340
TROG IMAT – A Randomised, Placebo-Controlled, Phase II Trial of Adjuvant Avelumab in Patients with Stage I-III Merkel Cell Carcinoma
Dr Wen Xu

Trials on Hold

1340 – 1345
TROG 17.11 C-POST – A Randomised, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab versus Placebo after Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma
Prof Danny Rischin

1345 – 1415
Horizon Scanning: Future Directions and Opportunities

Dr Charles Lin
Prof Sandro Porceddu
Dr Lachlan McDowell
Prof Danny Rischin
Prof Liz Kenny
Dr Andrew MacCann
A/Prof Puma Sundaresan
Dr Chris Wratten
A/Prof Brett Hughes

Chairs: Mr Dean Wilkinson & Dr Nick Hardcastle

1245 – 1250
Welcome and Introduction to the TRW
Dr John Shakeshaft

1250 – 1255
Sponsor’s Address
Mr Sean Watson

1255 – 1305
TROG RTQA: Update, Knowledge-Based Planning, Awards and More….
Mrs Alisha Moore

1305 – 1320
Sensitivity of Patient Specific Quality Assurance (SEAFARER)
A/Prof Joerg Lehmann

1320 – 1335
Australian Clinical Dosimetry Service – Updates, Collaborations and Focus for the Future (SABR, SRS & MR-Linac)
Ms Rhonda Brown

1335 – 1400
Collaborative Presentation – Peter MacCallum Cancer Centre, Royal Adelaide Hospital, Royal Brisbane and Women’s Hospital, Westmead Hospital
Dr Adam Yeo & Dr Jonathan Sykes

1400 – 1415
The Radiotherapy Atlas Contouring Tool (TRAC) for Automated Clinical Trial QA – The Future of Clinical Trial RTQA?
Mr Phillip Chlap

 

1415 – 1430 AFTERNOON BREAK
Meeting Hub | Meet with Delegates in the Meeting Hub
Exhibition | Browse the Exhibition
1430 – 1600 PLENARY 4: OPTIMISING THE COMBINATION OF NOVEL THERAPIES WITH RADIATION THERAPY IN OLIGOMETASTATIC DISEASE

TECHNICAL RESEARCH WORKSHOP: TECHNOLOGY DRIVEN CLINICAL TRIALS

Chairs: Dr Ben Chua & Dr Eric Hau Chairs: Prof Tomas Kron & Mr Fahim Siddiqi
1430 – 1450 Combining SABR and Drugs for Metastases Outside the Brain
A/Prof Shankar Siva
1430 – 1445
Pancreatic SBRT Motion Management: AGITG AG0118PS TROG 18.04 MASTERPLAN – Randomised Phase II Study of Mfolfirinox and STEreotactic Radiotherapy for Pancreatic Cancer with Locally AdvaNced Disease (Cat C | Open)
Dr John Shakeshaft
1450 – 1510 Combining Radiotherapy and Drugs for Brain Metastases
A/Prof Mark Pinkham
Speaker sponsored by
1445 – 1500
TROG 15.03 FASTRACKII – Focal Ablative STereotactic RAdiosurgery for Cancers of the Kidney – A Phase II Clinical Trial (Cat A | Open): Knowledge Based Planning and Imaging Sub-Studies
Dr Nick Hardcastle
1510 – 1525 Integration of Novel Treatments from the Medical Oncology Perspective
A/Prof Chee Lee
1500 – 1515
Liver SBRT Motion Management using KIM: USYD/TROG 17.03 LARK – Liver Ablative Radiotherapy Utilising Kilovoltage Intrafraction Monitoring (KIM) (Cat A | Open)
Dr Trang Nguyen
1525 – 1540 Ethics in Practice: Clinical Equipoise, and Navigating Unchartered Territory in Translational Research
Dr Linda Sheahan
1515 – 1530
Liver SBRT Planning and Treatment – Challenges and Opportunities: USYD/TROG 17.03 LARK
Mr Timothy Blacketer
1540 – 1600 Panel Discussion & Horizon Scanning 1530 – 1545
MRI Based Prostate Planning: TROG 18.01 NINJA (Novel Integration of New Prostate Radiation Schedules with adJuvant Androgen Deprivation) (Cat A | Open): Substudy – Update and what is Coming Next?
Prof Peter Greer
1545 – 1600
TROG 18.06 FIG (FET-PET in Glioblastoma) Trial (Cat A | Open) – Technical Challenges and Practice Changing Ideas
A/Prof Eng Siew Koh
1600 – 1700 EXPANDING THE TROG PORTFOLIO

 

1600 – 1630

Chairs: Ms Laurel Schmidt & A/Prof Joerg Lehmann

Technology Special Interest Groups – Update, Progress, Achievements: Particle Therapy and MRI in Radiation Therapy
Prof Farshad Foroudi & A/Prof Hien Le

1630 – 1645 Artificial Intelligence in Radiation Therapy: Is there a Role in Clinical Trials?
Prof Annette Haworth
1645 – 1700 EBRT Following Interventional Oncology – Scenarios, Challenges and Opportunities
Dr Richard Khor & Dr Dinesh Ranatunga
1700 – 1730

SPEED NETWORKING

Your opportunity to meet colleagues and speakers through small group meetings, to discuss a number of topics. Participants will be randomly allocated through a progression of six-person-five-minute video group chats.

Conversation Starters

17001705: Round 1

Professional topic -What do you see as the biggest challenge/opportunity facing research in radiation oncology?
Personal Topic
– What do you enjoy most about your job?

1705 – 1710: Round 2

Professional topic – Artificial intelligence – will your job ever be obsolete?
Personal Topic
– Space travel vs deep ocean submarine exploration – which would you choose if given the chance, and why?

1710 – 1715: Round 3

Professional topic – Do you think TROG should consider trials for brachytherapy?
Personal Topic
– If you could spend one day in someone else’s shoes, who would it be and why?

1715 – 1720: Round 4

Professional topic – What has been the greatest challenge/achievement of your career so far?
Personal Topic
– Which “bucket list” activity (that you have completed) most exceeded expectations and why?

1720 – 1725: Round 5

Professional topic – Have you ever knowingly used artificial intelligence based systems?
Personal Topic
– Procrastination – what is your personal productivity kryptonite?

1725 – 1730: Round 6

Professional topic – What advice would you give to someone just starting out in research?
Personal Topic
– Are you scared about how much your internet browser knows about you? Why/Why not?

1745 – 1830

SYMPOSIUM: CONSIDERATIONS OF THORACIC RADIATION IN THE IMMUNOTHERAPY ERA

1745 – 1750 Session Introduction
Prof Shalini Vinod
1750 – 1802

How do we Administer CRT to Unresectable Stage III NSCLC Patients with Consolidation IO Treatment in Mind?
A/Prof Gerry Hanna

1802 – 1814

Considerations for RT in ES-SCLC Patients Treated with Immunotherapy
Dr Eric Hau

1814 – 1830

Panel Discussion: Best Practice Shared Care Arrangements between Radiation and Medical Oncology

Prof Shalini Vinod
A/Prof Gerry Hanna
Dr Eric Hau

Dr Melissa Moore

 

WEDNESDAY 24 MARCH 2021

0745 – 0815 BREAKFAST SESSION: Digital Health Interventions (DHI) Echoing Patient’s Voice-Electronic Patient Reported Outcomes in Cancer Care
Prof Vesa KatajaSponsored by
0815 – 0845 BREAKFAST SESSION: From SFRT to Immunotherapy: Translational Advances in Radiation Research
Debanti SenguptaSponsored by
0900 – 1030 PLENARY 5: EMERGING TECHNOLOGIES
0900 – 0915

Chairs: A/Prof Peter Gorayski & Prof Paul Keall

New Techniques and Technologies Committee Update
Prof Tomas Kron & A/Prof Joerg Lehmann

0915 – 0935 Technical Considerations and Future Directions of Proton Therapy
Prof Sung Yong Park
0935 – 0955 Clinical Considerations and Future Directions of Proton Therapy
A/Prof Melvin Chua Lee Kiang
0955 – 1020 MRI Linac in Clinical Practice: Fully Adaptive Radiotherapy
Dr Jeremy De Leon
Speaker sponsored by
1020 – 1030 Panel Discussion
1030 – 1045

MORNING BREAK

Meeting Hub | Meet with Delegates in the Meeting Hub Exhibition | Browse the Exhibition

1045 – 1215 PLENARY 6: GENITOURINARY CANCER RESEARCH PORTFOLIO
Chairs: A/Prof Shankar Siva & Dr Stephen Chin
1045 – 1105 TROG 08.03 RAVES – A Phase III Multi-Centre Randomised Trial Comparing Adjuvant RT with Early Salvage RT in Patients with Positive Margins or Extra Prostatic Disease following Radical Prostatectomy (Cat A | Open)
Dr Maria Pearse & A/Prof Andrew Kneebone
1105 – 1125 TD 20.02 CHyPPR – A Phase 3 Randomised Controlled Trial of Conventional Versus HYpofractionated Post Prostatectomy Radiotherapy (Cat A | In Development)
Dr Stephen Chin
1125– 1140 TROG 19.06 DECREASE – DarolutamidE + Consolidation RadiothErapy in Advanced proStatE Cancer Detected by PSMA (Cat A | Start Up)
A/Prof Shankar Siva
1140 – 1150 ICR-CTSU/2015/10052 TROG 16.03 CORE – A Randomised Trial of Conventional Care versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases (Cat B | Open)
A/Prof David Pryor
1150 – 1215 Genitourinary Working Party Update and Strategy Meeting Summary
A/Prof Shankar Siva
Dr Stephen Chin
A/Prof David Pryor
Dr Jarad Martin
Prof Paul Keall
Ms Alison Brown
1215 – 1245

LUNCH BREAK

Meeting Hub | Meet with Delegates in the Meeting Hub Exhibition | Browse the Exhibition

1245 – 1415 PLENARY 7: BREAST CANCER RESEARCH PORTFOLIO
Chairs: Prof Boon Chua & Dr Peta Lonski
1245 – 1305 BIG 3-07/TROG 07.01 Randomised Phase III Study of Radiation Doses and Fractionation in Non-Low Risk DCIS of the Breast: 5-Year Main Analysis (Cat A | Open)
Prof Boon Chua
1305 – 1325 TROG 14.04 Heart Avoiding Radiation Therapy (HART): Final Analysis and Research Directions (Cat A | Closed)
Prof Tomas Kron
1325 – 1345 MRI-Guided Breast Radiotherapy: Background and Future Concept Possibilities
A/Prof Farshad Foroudi
1345 – 1410 Radiomics in Breast Cancer
Dr Will Rae
1410 – 1415 Automated Gross Tumour Volume Contour Generation in Radiomics Research
Prof Tomas Kron
1415 – 1430

AFTERNOON BREAK

Meeting Hub | Meet with Delegates in the Meeting Hub Exhibition | Browse the Exhibition

1430 – 1600 CLOSING PLENARY

 

1430 – 1440

Chairs: Prof Trevor Leong & A/Prof Sasha Senthi

Trial Update: CCTG SC24 TROG 17.06 – A Phase III Randomized Feasibility Study Comparing Stereotactic Body Radiotherapy (SBRT) Versus Conventional Palliative Radiotherapy (CRT) for Patients with Spinal Metastases (Cat B | Closed)
A/Prof Shankar Siva

1440 – 1450 Trial Update: CKTO 2006-04 TROG 08.04 PORTEC – Randomised Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma (Cat C | Open)
Dr Pearly Khaw
1450 – 1500 Trial Update: TROG 18.06 FIG – FET-PET in Glioblastoma (Cat A | Open)
A/Prof Eng-Siew Koh
1500 – 1520 Future Directions in Cranial Radiosurgery
A/Prof Matthew Foote
1540 – 1555 President’s Report (including TROG Awards)
Dr Giuseppe Sasso
1555 – 1600 Closing Remarks
Dr Renee Finnigan & Dr John Shakeshaft

* Please note this program is subject to change.

 

ASM Countdown

Important Dates

Registration

Now Open

Early Bird Registration Closes

5 February 2021